This product is currently not available for purchase.


A Clinical Laboratories Response to a Terrorist Assault with Anthrax. Edition No. 1

  • ID: 1908439
  • October 2009
  • 172 Pages
  • VDM Publishing House
1 of 3

The goal of this manuscript was to develop a clinical laboratory model for the early detection and initial response to a large scale covert bio- terrorist assault with anthrax spores. This study researched more than 100 published research articles from a variety of medical databases from 2001 through 2004, with an extensive background review on bio-terrorism prior to 2001 as well. In addition to the research meta-analysis this study conducted informal interviews with laboratory personnel, and performed several focus group sessions which included reference laboratory and hospital laboratory administrators. This study took into consideration the unique concerns of a covert assault, or assault that is not announced and not evident until mass casualties begin flooding into the local hospitals. Covert assaults with anthrax in particular can be successful do to the nature of Bacillus anthracis’s (Anthrax) ability to survive as a spore in adverse environments and then become infectious again when ingested by an unsuspecting host.

Note: Product cover images may vary from those shown
2 of 3

Leslie, King.
Dr. Leslie King earned a Bachelor’s degree in Clinical Laboratory Science from the University of Texas in 1994, followed by a Ph.D. in HealthCare Administration from Capella University in 2004. Dr. King has more than 20 years experience in the clinical laboratory field, with experience in hospital and reference laboratories.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.